1-5 of 5
Fei Ye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy

Kaustav P. Shah, Haocan Song, Fei Ye, Javid J. Moslehi, Justin M. Balko, Joe-Elie Salem, Douglas B. Johnson
Journal: Cancer Immunology Research
Cancer Immunol Res (2020) 8 (7): 851–855.
https://doi.org/10.1158/2326-6066.CIR-19-0986
Published: 01 July 2020
View article titled, Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy
Open the PDF for Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy in another window
Includes: Supplementary data
Journal Articles

Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells

Michael W. Pickup, Philip Owens, Agnieszka E. Gorska, Anna Chytil, Fei Ye, Chanjuan Shi, Valerie M. Weaver, Raghu Kalluri, Harold L. Moses, Sergey V. Novitskiy
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (9): 718–729.
https://doi.org/10.1158/2326-6066.CIR-16-0311
Published: 31 August 2017
View article titled, Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells
Open the PDF for Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells in another window
Includes: Supplementary data
Journal Articles

Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma

Daniel Y. Wang, Zeynep Eroglu, Alpaslan Ozgun, Paul D. Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard W. Joseph, Rizwan Haq, Patrick A. Ott, F. Stephen Hodi, Jeffrey A. Sosman, Douglas B. Johnson, Elizabeth I. Buchbinder
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (5): 357–362.
https://doi.org/10.1158/2326-6066.CIR-16-0287
Published: 01 May 2017
View article titled, Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Open the PDF for Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

Amanda Shreders, Richard Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman, Douglas B. Johnson
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (7): 569–573.
https://doi.org/10.1158/2326-6066.CIR-15-0281
Published: 30 June 2016
View article titled, Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Open the PDF for Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

Douglas B. Johnson, Debra L. Friedman, Elizabeth Berry, Ilka Decker, Fei Ye, Shilin Zhao, Alicia K. Morgans, Igor Puzanov, Jeffrey A. Sosman, Christine M. Lovly
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (5): 464–469.
https://doi.org/10.1158/2326-6066.CIR-14-0217
Published: 03 May 2015
View article titled, Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
Open the PDF for Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center in another window